Clear Street initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $33 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with a Buy at TD Cowen
- Summit Therapeutics’ Ivonescimab: A Potential Game-Changer in NSCLC Treatment with Promising HARMONi Trial Results
- BioNTech price target lowered to $132 from $140 at Morgan Stanley
- Summit Therapeutics’ Earnings Call: Ivonescimab’s Promising Progress
- Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue